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Objectives.microRNAs comprise a family of small, non-coding RNAs, which regulate gene expression at the
posttranscriptional level. Multiple studies implicated important roles of microRNAs in various malignancies
including endometrioid endometrial carcinoma (EEC). qPCR is widely used in the studies investigating microRNA
expression. Relative quantiﬁcation of microRNA expression requires proper normalization methods and endoge-
nous controls are widely used for this purpose. The aim of this study was experimental identiﬁcation of stable
endogenous controls for normalization of microRNA qPCR expression studies in EEC.
Methods. Expression of twelve candidate endogenous controls (miR-16, miR-26b, miR-92a, RNU44, RNU48,
U75, U54, U6, U49, RNU6B, RNU38B, U18A) was investigated in tissue samples obtained from 45 patients (30
EEC, 15 normal endometrium) using qPCR. Stability of candidate endogenous controls was evaluated using Norm-
Finder, geNorm, BestKeeper and equivalency test. The results were then validated using larger group of samples.Results. RNU48, U75 and RNU44 were identiﬁed as stably and equivalently expressed between malignant and
normal tissues. Both NormFinder and geNorm indicated that those three snRNAs were optimal for qPCR data
normalization in EEC tissues.
Conclusions. In conclusion, we suggest that average expression of those snoRNAs could be used as a reliable
endogenous control in microRNA qPCR studies in endometrioid endometrial cancer. In addition to identifying
suitable endogenous controls in EEC, our study presents an appropriate strategy for validation of candidate
reference genes for any microRNA qPCR study.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Endometrial cancer is the most commonmalignancy of the female
reproductive tract and it is responsible for over eighty thousand new
cancer cases in Europe each year [1]. The 5-year survival and progno-
sis is fairly good in patients diagnosed with early disease, whereashair andDepartment of Human
-090, Lublin, Poland. Fax: +48
nc. Open access under CC BY-NC-ND licenseadvanced stages are still connected with high mortality and survival
rates less than 20% [2]. This is due to lack of screening methods for
precancerous and early disease and not sufﬁcient treatment modali-
ties for advanced disease. Multiple molecular pathways have been
investigated in endometrial cancer in the search for novel diagnostic,
prognostic and treatment strategies [3]. New hypotheses on endome-
trial cancer pathogenesis emerged with the discovery of microRNAs
(miRNAs) and their role in posttranscriptional gene expression regula-
tion [4–6]. MiRNAs are implicated as important factors in carcinogenesis
because they target and regulate expression of oncogens and tumor sup-
pressor genes [6]. Recent studies reported altered expression of several
miRNAs in endometrioid endometrial cancer (EEC). A large number of
miRNAs were found up-regulated in EEC tissues with miR-200 family,
miR-9, miR-203, miR-205, and miR-210 reported by at least two or.
Table 1
Characteristics of endometrioid endometrial cancer patients.
Characteristic Fresh RNAlater incubated tissues (n) FFPE tissues (n)
FIGO stage
IA 14 16
IB 9 8
II – 5
IIIA 1 2
IIIB 3 –
IIIC1 3 5
IIIC2 – 6
IVA – 1
IVB – 1
Grade
1 13 14
2 14 14
3 3 15
Myometrial invasion
b0.5 of
myometrial thickness
15 18
≥0.5 of
myometrial thickness
15 26
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miR-214, miR-99a,b, miR-199b, miR-100, miR-20a, miR-221, miR-222,
and miR-424 were found down-regulated [7–18]. Moreover, miRNA
tissue signatures have the potential of being used not only as diagnostic
markers, but also as prognostic factors in EEC for they were found
predictive of the recurrence, lymph node metastases and survival
[17,18]. Furthermore, recently published studies suggest that miRNA
plasma signatures could be used to distinguish patients with EEC from
healthy controls [17–19]. Functional studies performed to date showed
that single miRNAs (miR-145, miR-200 family, miR-204, miR-206)
inﬂuenced proliferation, migration and survival of endometrial cancer
cells [8,9,11,20–22]. Such observations are promising in regard to
the development of novel diagnostic and therapeutic modalities. At
the same time analysis of miRNA expression is difﬁcult and many
methodological issues are still not fully determined [23,24]. Therefore
translational studies, which aim to discover new therapeutic or diag-
nostic approaches, should be based on the stringent and reliable meth-
odology. One important issue in miRNA expression studies relates to
proper normalization strategy, which is necessary to minimize system-
atic and technical bias introduced at each step of miRNA quantiﬁcation
process [25–27]. At present there is no consensus on the normalization
strategy that should be used in miRNA qPCR studies. Three methods of
miRNAnormalization have been described in the literature: endogenous
control-based, global mean expression and plate normalization factor
[28–30]. The latter two methods are however suitable for large-scale
studies. Therefore endogenous controls are still the method of choice
for experiments focused on expression analysis of few miRNAs, which
are often performed in translational studies.
Endogenous controls should be stably expressed and at the same
time should undergo the same technical variation as target miRNAs.
Although some authors suggested that certain miRNAs could be used
as universal endogenous controls, the subsequent studies indicated
that there was a possibility of their regulation in various diseases [28].
Therefore, similarly to mRNA expression analysis, a proper normaliza-
tion of miRNA quantiﬁcation requires a careful choice and validation
of endogenous controls in the representative sample of the studied
population [31].
Our search of miRNA proﬁling studies in endometrial cancer
revealed that they relied on arbitrarily chosen endogenous controls.
No previous report described an experimental identiﬁcation and
validation of suitable endogenous controls for normalization in endo-
metrial cancer.
Thus we aimed to experimentally identify the most stable endoge-
nous controls for normalization of miRNA qPCR expression studies in
endometrioid endometrial cancer, which consists the most common
histological type of the uterine malignancy. The candidate non-coding
RNAs (ncRNAs) including nine snRNAs and snoRNAs and three miRNAs
were chosen based on the previous studies,which suggested their stable
expression across a range of tissues and cell lines [28,31–34]. In addition,
none of the candidate non-coding RNAs chosen for analysis was regulat-
ed in any of the previously published endometrial cancer studies.
Materials and methods
Sample collection
Fresh tissue sampleswere obtained from45patients (30 EEC, 15NE)
and FFPE specimens from 58 patients (44 EEC, 14 NE). Preoperative
diagnosis of EEC was subsequently conﬁrmed by histological examina-
tion of the specimens obtained during surgery. FIGO staging was
performed according to 2009 FIGO classiﬁcation and EEC specimens
were classiﬁed, according to the 2002 WHO classiﬁcation in G1, G2 or
G3. Study design was revised and granted approval from Medical
University of Lublin Ethical Committee. Written informed consent was
obtained from each study participant. Detailed characteristic of EEC
patients was presented in Table 1.All fresh tissue samples were collected during hysterectomies with-
in 15 min after uterus excision. Normal endometrial samples were
derived from patients operated due to pathologies other than of endo-
metrial origin and comprised comparable numbers of proliferative
and secretary phase endometrium. Immediately after sampling tissues
were immersed and incubated in RNAlater (Ambion) for 24 h in 4 °C.
After incubation tissues were stored in−80 °C until RNA extraction.
Candidate endogenous controls
The candidate endogenous controls (ECs) were chosen based on
the literature suggesting their high abundance and stable expression
across large panels of tissues and cell lines [28,31–34]. Characteristics
of candidate ECs were presented in Table S5. The search of the litera-
ture conﬁrmed that candidate non-coding RNAs included in our anal-
ysis were not regulated in endometrioid endometrial cancer tissues.
RNA isolation and analysis, reverse transcription and quantitative PCR
RNA isolation and analysis was performed using the mirVANA™
miRNA Isolation Kit (Ambion) RecoverAll™ Total Nucleic Acid
Isolation Kit for FFPE tissues (Ambion) for fresh and FFPE tissues
respectively according to the manufacturer's protocol. RNA was
reverse transcribed using the TaqMan® MicroRNA Reverse Tran-
scription Kit and speciﬁc primers (Applied Biosystems). Single tube
TaqMan® MicroRNA Assays and TaqMan® 2× Universal PCR Master
Mix, No AmpErase® UNG (Applied Biosystems) were utilized for
performing qPCR. Detailed description of the methods is provided
in the Supplementary methods ﬁle (Supplementary ﬁle 2).
Data analysis
Raw qPCR data obtained from tissue samples were initially
normalized with inter-plate calibrators and adjusted for reaction
efﬁciency and were used as input in further stability analyses.
Stability of candidate ECs was evaluated using three different soft-
ware applications, which are commonly utilized in the experimental
validation of reference genes: NormFinder, geNorm and BestKeeper
[35–37]. NormFinder is an ANOVA-based model, which returns stan-
dard deviation (SD) value, accumulated SD (Acc. SD) value and stability
value, named variability. Analyses performed in NormFinder may con-
sider groups and enable determination of intra-group and inter-group
variations which make it possible to detect regulation of ECs between
subgroups within the studied population [37,38]. This is the most
important difference between NormFinder and other available
Fig. 1. NormFinder analyses performed without taking groups into account; (a) panel
of 12 candidate genes (in the group of 32 samples); (b) panel of 9 candidate genes
(in the group of 45 samples).
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BestKeeper are similar and identify best genes basing on pair-wise
comparison between genes [35,36]. GeNorm calculates the stability
values (M) for all candidate ECs using a step-wise pairwise variation
excluding candidates with the lowest stability. The procedure is repeat-
ed until the two most stable ECs are predicted. Therefore geNorm
sequentially eliminates non-optimal genes and returns the best pair of
genes, characterized by stability value, named M value. The M value of
1.5 was deﬁned as the upper limit for candidate ECs. Authors of geNorm
suggested that values between 0.5 and 1.0 were characteristic for
heterogeneous sample groups comprising healthy and cancer tissues
[35]. geNorm also calculates the optimal number of genes suitable for
normalization and returns the Vn/Vn + 1 value of such combination
[35]. In the current study all candidate ECs included in the panel yielded
M values below the threshold value of 1.5 and eight of them — below
1.0, which indicated their suitability for study design. BestKeeper
determines gene stability basing on the standard deviations and
coefﬁcients of variance [36].
In the presented studywe also investigated equivalent expression be-
tween EEC and normal endometrium groups using equivalence test and
the fold change cut-off of 3 ([−ε; ε] = [log21/3; log23] = [−1.585;
1.585]) [39].
The stability of candidate ECs was assessed using three algorithms,
which are commonly utilized in the experimental validation of refer-
ence genes: geNorm, NormFinder and BestKeeper. The mathematical
algorithms behind geNorm and BestKeeper are similar [35,36]. GeNorm
calculates the stability values (M) for all candidate ECs using a step-wise
pairwise variation excluding candidates with the lowest stability. The
procedure is repeated until the two most stable ECs are predicted. The
M value of 1.5 was deﬁned as the upper limit for candidate ECs. Authors
of geNorm suggested that values between 0.5 and 1.0 were characteris-
tic for heterogeneous sample groups comprising healthy and cancer tis-
sues [35]. Different statistical approaches are applied in NormFinder,
which is an ANOVA-based model. The most important difference be-
tween the two algorithms consists in possibility of considering the
groups in NormFinder, which enables determination of intra-group
and inter-group variations [37].
In the current study all candidate ECs included in the panel yielded
M values below the threshold value of 1.5 and eight of them — below
1.0, which indicated their suitability for study design.
In order to perform relative quantiﬁcation of miRNA expression in
the validation part of the study mean Cq values of replicates (three RT
and two qPCR replicates for each sample) were normalized with IPCs
and adjusted for reaction efﬁciency and then normalized using four
different normalization strategies: geometric mean of three experi-
mentally chosen, stable ECs (RNU48, RNU44 and U75), miR-92a
alone, geometric mean of RNU48/miR-92a and geometric mean
(GM) of all ampliﬁed genes (RNU48, RNU44, U75 and 17 miRNAs),
that were co-ampliﬁed as part of another study [17].
Normalized qPCR data were log transformed before statistical anal-
ysis. Distribution of data was estimated with D'Agostino–Pearson
normality test. Fisher test was used to assess equality of variances.
Student's t-test (with or without Welch correction) or Mann–Whitney
test was used to compare between the groups as appropriate. Results
are presented as mean with 95% conﬁdence intervals (95% CI) or a
fold change (FC) with 95% CI. Data analysis was performed using
GenEx 5.3.4 (MultiD) and MedCalc (MedCalc Software) version 12.2.1.
All statistical tests were two-sided and p b 0.05 was considered to
indicate statistically signiﬁcant difference.
Results
Expression levels of candidate endogenous controls
All candidate ECs were expressed at suitable levels both in normal
and in EEC tissues. In the case of RNU38B, RNU6B andU18A ampliﬁcationwas performed in 32 samples. Cq values of all candidate ECs were char-
acterized in Supplementary Tables S1 and S2.
Comparison of raw Cq values revealed signiﬁcant differences in
the case of miR-16 (p = 0.009), RNU38B (p = 0.018) and U18A
(p b 0.0001) (Fig. S1). Using the fold change cut-off of 3 ([−ε;
ε] = [log21/3; log23] = [−1.585; 1.585]) the equivalent expression
between normal and EEC groups was not conﬁrmed for four candi-
date ECs: miR-16, miR-26b, miR-92a and U18A.Analysis of candidate endogenous controls stability
NormFinder analysis
NormFinder analysis was initially conducted without considering
the groups in the panels of 12 candidate genes (in the group of 32 sam-
ples) and 9 candidate genes (in the group of 45 samples) and the results
are presented in Fig. 1. In both analyses RNU48 was identiﬁed as the
most stable ncRNA followed by RNU44 and U75. Both analyses were
also very concordant in terms of least stable ncRNAs: U49 andmiR-26b.
Following, the EEC and NE groups were taken into account in order
to inspect the inter-group variation, which is a differential expression
counted based on average expression relative to the global mean of
the genes in the panel. According to the assumption behindNormFinder
algorithm, inclusion of potentially regulated candidate genes in the
panel could interfere with the analysis. The threshold inter-group vari-
ation to disqualify genes from the panel depends on the difference
between studied groups that is expected, however the expected regula-
tion should usually be below0.1 to 0.2 cycles. In the presented studywe
Table 2
geNorm M values and NormFinder variability after excluding miR-92a, miR-26b and
U18A from the panel of candidate ECs.
Rank NormFinder geNorm
Candidate EC ρig Candidate EC M value
1 U75 0.098 RNU44 0.739
2 RNU48 0.101 RNU48 0.739
3 RNU44 0.131 U75 0.843
4 U6 0.181 miR-16 0.939
5 miR-16 0.191 U54 0.995
6 U54 0.193 U6 1.041
7 U49 0.295 U49 1.158
Best combination of two ECs
U75/RNU48 ρig 0.076
Best two ECs RNU44, RNU48
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inter-group variation between EEC and NE groups revealed the highest
variability values in the case of miR-92a, miR-26b and U18A (Table S3).
Inter-group variation analyses performed when groups were distin-
guished based on FIGO stage and histological grading conﬁrmed those
results (Table S4). ThereforemiR-92a,miR-26b andU18Awere excluded
from the panel and analyses were repeated without considering the
groups. The results obtained in both panels of candidate ECs were
almost identical (Fig. 2). The highest decrease of Acc. SD was achieved
for the three most stable ECs (RNU48, RNU44, U75) and addition of
more ECs did not improve this result signiﬁcantly (Fig. 2). The variabil-
ity obtained for the best pair of ECs (RNU48/U75), when the groups
were considered was as low as 0.076 (Table 2).
geNorm analysis
geNorm analysis identiﬁed RNU48, RNU44 and U75 as the most
stable genes in two analyses performed in panels of 12 candidate
genes (in the group of 32 samples) and 9 candidate genes (in the
group of 45 samples). miR-92a was ranked as the fourth most stable
reference gene in the geNorm analysis performed when the panel ofFig. 2. NormFinder analyses performed without taking groups into account after
excluding miR-92a, miR-26b and U18A; (a) panel of 9 candidate genes (in the
group of 32 samples); (b) panel of 7 candidate genes (in the group of 45 samples);
(c) accumulated SD obtained in NormFinder analysis after excluding miR-92a,
miR-26b and U18A (in the group of 45 samples).nine genes was considered (Fig. 3a–b). Determination of number of
genes required for optimal normalization performed by geNorm
calculates the pairwise variation (Vn/Vn + 1) between sequential
normalization factors. According to geNorm analysis performed in
the panel of 12 genes normalization performed to average expression
of four ncRNAs (RNU48, RNU44, RNU75, RNU38B) yielded the thresh-
old value of 0.152. When the analysis was repeated in the panel in-
cluding nine candidate ECs, ﬁve ncRNAs (RNU48, RNU44, U75,
miR-92a, U54) yielded Vn/Vn + 1 value of 0.153 (Fig. 3c). However,
this combination of ECs included miR-92a, which showed high
inter-group variation in the NormFinder analysis.BestKeeper analysis
BestKeeper determines the stability of candidate reference genes
basing on the coefﬁcient of variation multiplied by 100. The lowest
CqCV% value counted by BestKeeper was attributed to RNU38B, which
was ranked fourth in the analyses performed by NormFinder and
geNorm. However, the three most stable ECs ranked by NormFinder
and geNorm were also characterized by fairly low CqCV% values of
3.63 (U75), 3.73 (RNU48) and3.77 (RNU44). On the other hand ncRNAs,
which were identiﬁed the least stable by NormFinder and geNorm
presented the highest CqCV% values of 6.66 (miR-26b), 6.2 (U18A) and
4.86 (U49) (Table S1).Validation of RNU48, RNU44 and U75 expression stability
In order to evaluate the expression stability of the three chosen
ECs we compared their expression in the same group of patients,
but with utilization of different fresh tissue samples for RNA isolation
and different qPCR protocols. ECs were further evaluated in the new
population of patients from which we obtained FFPE specimens. The
results showed no difference in mean Cq values in the fresh tissue
group, whereas in the FFPE group differences between Cq values
were found for RNU48 and U75 (Figs. S2, S3).Effect of reference genes on relative expression of target miRNAs
In order to evaluate the effect of candidate ECs on the target miRNA
expression results, we assessed expression of ﬁve targetmiRNAs, which
were previously reported up-regulated in EEC (miR-9, miR-141, miR-
183, miR-200a, and miR-200c), using four different normalization
strategies: geometric mean of RNU48/RNU44/U75, miR-92a alone,
geometric mean of RNU48/miR-92a and geometric mean (GM) of all
ampliﬁed genes.
The qPCR data used in this validation procedure was in part
presented in our previous report [17] and was obtained basing on
miRNA quantiﬁcation performed in 104 tissue samples. The results
are presented in Table 3.
Fig. 3. geNorm analyses; (a) analysis performed in the panel of 12 candidate genes (in the
group of 32 samples); (b) analysis performed in the panel of 9 candidate genes (in the
group of 45 samples); (c) determination of the optimal number of ECs for normalization.
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Since their discovery miRNAs emerged as important molecules in
cancer development, pathogenesis and progression [4]. They are also
suggested as efﬁcient markers in cancer diagnostics and outcome
prediction [4]. Several studies are being conducted exploring treatment
options associated with modulations of miRNA levels in vitro and in
vivo. Any research conducted in miRNA ﬁeld requires a reliable meth-
odology, which enables accurate and biologically relevant quantitation
of miRNA levels [25–27,31]. qPCR is one of the methods commonly
used for this purpose. Similarly to mRNA expression analysis, miRNAquantitationwith qPCR requires a proper normalization strategy to cor-
rect for non-biological variations [26,31]. As single miRNAs are thought
to regulate hundreds of genes, proper normalization of miRNA studies
may have a lot larger impact on biological relevance of acquired data
in comparison to mRNA expression analysis. Although to date there is
no consensus on miRNA qPCR data normalization, most experts agree
that no singlemiRNA or small RNA can be used as a universal normaliz-
er and the choice of optimal endogenous controls should be performed
experimentally for each study design [31].
Involvement of miRNAs in the biology of EEC has been suggested
in a number of studies, many of which applied qPCR and relative
quantitation based on endogenous controls as a method of expression
analysis. To the best of our knowledge none of those studies reported
validation of the ECs used for normalization [7–15]. It is therefore the
ﬁrst report to describe a systematic and experimental assessment of
candidate ECs, which could be used for normalization of miRNA
qPCR data in EEC tissues. Due to the lack of data on miRNA stability
in EEC, the panel of candidate ECs used in our study was chosen
based on their high expression and stability in other normal and
tumor tissues [28,31–34]. We also searched the EEC miRNA literature
to make sure that none of the candidate miRNAs was previously
reported regulated in EEC tissues [7–16].
Analyses performed by our group revealed that RNU48, RNU44
and U75 were the most stable ECs in EEC tissues. Both NormFinder
and geNorm indicated that those three snRNAs were optimal for
qPCR data normalization in EEC tissues. RNU48, RNU44 and U75
were also equivalently expressed between normal and cancer
samples. RNU38B was highly ranked by BestKeeper and indicated as
the fourth most stable reference gene in geNorm analysis. However,
equivalency test did not conﬁrm its equivalent expression between
normal and cancer tissues. The algorithms were also very concordant
in indication of least stable ECs, which further supported our results.
It was suggested that a proper normalization strategy for relative
gene quantiﬁcation should include at least three to ﬁve ECs [40].
However, the choice of the number of genes used for normalization
often depends on practical and economical rationales. NormFinder
analysis performed in our study revealed that the highest decrease
in variation was achieved with the three most stable ECs (RNU48,
RNU44, U75). Addition of more ECs did not improve this result
remarkably.
The three best ECs identiﬁed in the presented study belong to the
class of small nucleolar RNAs (snoRNAs), approximately 70 nucleotides
in length, which is responsible for site-speciﬁc chemical modiﬁcation of
target RNAs [41]. Small nucleolar and small nuclear RNAs were pro-
posed as ECs for miRNA studies due to their similar size and high abun-
dance in tissues [32]. A set of small RNAs was investigated in the large
panel of tissues and cell lines and many of those molecules were
found stably expressed [32]. However, some authors suggested that
snRNA and snoRNAs are not optimal ECs for miRNA studies, as they
may not reﬂect physicochemical properties of miRNA molecules [40].
Due to their larger size theymay present different RNA isolation and re-
verse transcription efﬁciency as well as lower stability in comparison to
miRNAs. Thus their utility was suggested less advisable, when the dif-
ferences in overall abundance of miRNA could be anticipated, including
experiments affecting miRNA biogenesis machinery or involving vari-
ous tissues and cell lines in one analysis [24]. Nevertheless themost sta-
ble ECs chosen based on the analyses performed in this study belonged
to small nucleolar RNA class. Although the candidate EC panel used in
our study included three candidate miRNAs, which were previously
found stably expressed in various tissues and cell lines, their expression
did not appear stable in the studied set of EEC and NE samples.
In many studies the initial evaluation of candidate ECs was
performed using a t-test performed on non-normalized Cq values,
which in fact assume normalization to total RNA. In the case of
miRNA studies such approach may be far more misleading than in
mRNA expression proﬁling as miRNAs consist a very small fraction
Table 3
Effect of different normalization strategies on relative expression of target miRNAs.
miRNA Normalization
RNU48, RNU48, U75 miR-92a U48, miR-92a GM
FC p FC p FC p F p
miR-9 5.46 0.0002 −2.48 0.005 1.82 0.055 2.82 0.009
miR-92a 15.63 0.0002 – – – – 7.37 b0.0001
miR-141 3.80 0.003 −3.2 0.001 1.16 0.64 1.94 0.011
miR-183 3.44 b0.0001 −4.22 b0.0001 1.18 0.54 1.75 0.028
miR-200a 3.61 0.0003 −3.61 0.0016 1.17 0.63 1.66 0.008
miR-200c 4.32 b0.0001 −2.89 0.00016 1.37 0.1 2.44 b0.0001
FC — fold change, GM — geometric mean of all ampliﬁed miRNAs/snoRNAs.
593A. Torres et al. / Gynecologic Oncology 130 (2013) 588–594of total RNA and currently available measuring strategies do not enable
reliable assessment of miRNA concentration in total RNA sample.
Moreover such measurements can be strongly biased by RNA quality
[25]. In our study ncRNAs characterized by high inter-group variation
(NormFinder) were also differentially expressed based on t-test results,
whereas in the case of RNU48, RNU44 and U75, no difference in expres-
sionwas found in the t-test analyses performed in fresh tissues. Howev-
er, when non-normalized Cq values of RNU48, RNU44 and U75 from
EEC and control FFPE specimens were compared signiﬁcant differences
were found in expression of U75 and RNU48. As it was previously men-
tioned comparison of raw Cq values may not reﬂect true biological var-
iation and in the case of FFPE specimens this result could be biased
by RNA quality. Although it was proven that miRNAs are stable and re-
sistible to chemical processing of FFPE specimens the recent study
presented by Becker et al. indicated that total RNA quality adversely
inﬂuenced results of miRNA proﬁling [25]. Such ﬁndings indicate that
comparisons between groups comprised of fresh and FFPE samples
could lead to erroneous results. Therefore, if the study involves both
fresh and FFPE specimens the caution needs to be taken to include
equal numbers of the two sample types in both normal and abnormal
groups in order to minimize the risk of technical variation.
In addition to identifying stable ECs in EEC, our study revealed an im-
portant methodological issue, which should be concerned when choos-
ing genes for the panel of candidate ECs. Inclusion of regulated genes in
the panel analyzed with geNorm could lead to erroneous results, as this
algorithm does not consider inter-group variation in gene expression. In
our study geNorm rankedmiR-92a the fourthmost stable gene,whereas
in NormFinder analysis miR-92a showed high inter-group variation. In
order to evaluate such discordant results we decided to evaluate the
differences in target miRNA (miR-9, miR-141, miR-183, miR-200a, and
miR-200c) expression results after normalization to: geometric mean
of RNU48, RNU44, and U75, miR-92a alone and geometric mean of
RNU48 andmiR-92a. In additionwe have also performed normalization
to the geometric mean (GM) of all ampliﬁed miRNAs and snoRNAs (20
molecules), as it was recently proposed that suchnormalizationmethod
could be efﬁciently used in smaller scale experiments [25]. To our
surprise, the results obtained with miR-92a alone or a combination
miR92a/RNU48 used as normalizers, showed signiﬁcant differences
compared to the results reached after normalization with the combina-
tion of RNU48, RNU44, RNU75 or GM. Interestingly, the latter two nor-
malization strategies produced results, which were quite concordant.
To the best of our knowledge this is the ﬁrst systematic approach
to experimental identiﬁcation of ECs for endometrioid endometrial can-
cer miRNA qPCR studies. In most of the previous studies various
snRNAs, snoRNAs and rRNAs were used for normalization and authors
did not report their experimental validation. Few studies were recently
published discussing the subject of miRNA qPCR data normalization
in other malignances and diseases. When compared to the results
presented in those papers the stability values calculated for the best
set of ECs in our study were similar or better. Davoren et al. examined
stability of nine candidate ECs in breast cancer tissues and the pair of
best reference genes yielded higher variability (0.221) and M (1.473)values in comparison to our results. Moreover, all of the EC combina-
tions yielded V values above 0.15, as counted by geNorm [42]. The re-
sults obtained by Chang et al. in their colorectal cancer study revealed
quite highM value of 0.994 for the best pair referencemiRNAs, whereas
the variability counted by NormFinder for the same pair was very low
(0.003). The lowest V value in that study was 0.204 and was achieved
with the normalization performed using ﬁve ECs [43]. Carlsson et al.
found RNU24, RNU44 and RNU48 to be the most stable ECs in prostate
cancer tissues [44]. NormFinder indices obtained by Shen et al. in uter-
ine cervical tissues yielded variability of 0.176 for best single EC
(miR-23a) [45]. In our study the variability of the best normalizer was
very similar and yielded 0.1. In concordance with our results Shen et
al. found a signiﬁcant difference inmiR-26a expression betweennormal
and malignant samples. Further corresponding with our ﬁndings, U6
that is the most commonly used EC, was characterized by high M
value in that study [45].
In conclusion, the results obtained using different statistical ap-
proaches were very concordant and indicated that RNU48, U75 and
RNU44 were stably expressed in endometrioid endometrial cancer
tissues and that combination of those snoRNAs could be used for
normalization in miRNA qPCR studies in that malignancy. Moreover,
we found that some of the small RNAs, which were previously used in
EEC miRNA studies, should not be considered suitable for normaliza-
tion, as theywere not stably expressed in EEC tissues. It is generally stat-
ed that each qPCR study should begin with experimental validation of
ECs. In addition to identifying suitable ECs in EEC, our study presents
an appropriate strategy for validation of candidate reference genes for
any miRNA qPCR study.
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